Cerebral Venous Thrombosis Treatment in Children and Neonates Under 18 Years

Clinical Scenario

This protocol applies to patients younger than 18 years — including neonates and children — presenting with acute cerebral venous thrombosis (CVT).

Patient Population

Pediatric CVT spans a wide age range from the neonatal period through adolescence. The management approach in this population is distinct from adult protocols and is specifically structured for patients under 18 years of age.

Treatment Approach

Initial management involves parenteral anticoagulation as the first-line intervention, with subsequent anticoagulant therapy continuing for a defined period — the specific agents, sequence, and duration are detailed in the full protocol.More in full protocol ›

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1161/STR.0000000000000456

The management of acute CVT in children typically involves LMWH or unfractionated heparin.

Parenteral anticoagulation is also the first-line treatment, followed by LMWH, VKA, or rivaroxaban for at least 6 weeks.

In the EINSTEIN-Jr trial (Oral Rivaroxaban in Children With Venous Thrombosis), after initial heparinization, 114 children with confirmed CVT were randomized (2:1) to 3 months of rivaroxaban or standard anticoagulation (continuing heparin or switching to oral VKAs).

View source ↗